Identifying tumor cell vulnerabilities in recurrent/progressive human medulloblastomas by single-cell RNA-seq

The ambition reflected in this proposal is a product of robust collaboration across clinical/laboratory/bioinformatics experts within our team and external collaborators. Since MB is a rare disease, we need to extend our collaboration to centers/consortium with larger number of patients to be able to profile patient-matched recurrent tumors before and after treatment. Moreover, our scRNA-seq data can be integrated with the genetic data generated by the CBTTC, that can provides both our lab and CBTTC with means to better understand MB biology. We are currently collaborating with Karolinska University Hospital (Sweden), Sahlgrenska University Hospital in Gothenburg (Sweden) and Oslo University Hospital (Norway).